INM InMed Pharmaceuticals
- 0.2420
- -0.0219-8.30%
- 0.2404
- -0.0016-0.66%
InMed Pharmaceuticals News
Why Pinterest Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket
Shares of Pinterest, Inc (NYSE:PINS) rose sharply in today's pre-market trading following strong first-quarter earnings and upbeat second-quarter guidance.Pinterest's first-quarter revenue increased n
Express News | InMed Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/644,484 Titled "Metabolic Engineering Of E. Coli For The Biosynthesis Of Cannabinoid Products"
Why Tesla Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Shares of Tesla, Inc. (NASDAQ:TSLA) rose sharply in today's pre-market trading following first-quarter results.Tesla posted weaker-than-expected earnings and sales results for its first quarter on Tue
InMed Pharmaceuticals Welcomes Alzheimer's Expert
InMed Appoints Dr. David G. Morgan, PhD, a Leading Alzheimer's Expert, to the Company's Scientific Advisory Board
Vancouver, British Columbia–(Newsfile Corp. – April 18, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the research, development, manufacturing, and commercia
InMed Pharmaceuticals Preclinical Success With INM-089
Express News | InMed Pharmaceuticals INM-089 Presented Neuroprotection Of Photoreceptors As Well As Improved Photoreceptors Function; Improved Integrity Of Retinal Pigment Epithelium; And Reduction In Extracellular Autofluorescent Deposits, A Hallmark Of Dry AMD
Express News | InMed Pharmaceuticals Provides Update On INM-089 In The Treatment Of Dry Age-Related Macular Degeneration; Small Molecule Drug Acting As A Preferential Signaling Ligand For CB1/CB2
Express News | InMed Pharmaceuticals Inc - Small Molecule Drug Acting as a Preferential Signaling Ligand for CB1/CB2
Express News | InMed Provides Update on Inm-089 in the Treatment of Dry Age-Related Macular Degeneration
InMed Provides Update on INM-089 in the Treatment of Dry Age-Related Macular Degeneration
Small molecule drug acting as a preferential signaling ligand for CB1/CB2 Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical
InMed Pharmaceuticals Excites With Alzheimer's Breakthrough
InMed Pharmaceuticals Receives Nasdaq Extension
InMed Granted 180-Day Extension to Achieve Nasdaq Minimum Bid Compliance
Vancouver, British Columbia–(Newsfile Corp. – March 20, 2024) – InMed Pharmaceuticals Inc. (NASDAQ: INM) ("InMed" or the "Company"), a leader in the manufacturing, development and commercialization of
Express News | InMed Pharmaceuticals Has Received A Notice Of Allowance For Its U.S. Patent Application 16/098,324 Titled "Use Of Topical Formulations Of Cannabinoids In The Treatment Of Epidermolysis Bullosa And Related Connective Tissue Disorders"
InMed Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed higher by over 450 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders
InMed Pharmaceuticals(INM.US) Director Buys US$14,625 in Common Stocks
$InMed Pharmaceuticals(INM.US)$ Director HULL ANDREW purchased 37,500 shares of Common Stocks on Feb 21, 2024 at an average price of $0.39 for a total value of $14,625.Source: Announcement What is sta
Charles & Colvard And 3 Other Stocks Under $2 Insiders Are Buying
The Dow Jones index closed higher by around 0.1% on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders int
InMed Pharmaceuticals(INM.US) Officer Buys US$14,921.92 in Common Stocks
$InMed Pharmaceuticals(INM.US)$ Officer ADAMS ERIC A purchased 41,600 shares of Common Stocks on Feb 20, 2024 at an average price of $0.3587 for a total value of $14,921.92.Source: Announcement What i
InMed Pharmaceuticals Releases Q2 2024 Financial Snapshot
Analysis
Price Target
No Data
